Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag +/- All-trans Retinoic Acid in Primary ITP
NCT07278908Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of tretinoin in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tretinoin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07278908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07278908.